Inovio Pharmaceuticals, Inc. (INO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $1.16. The rating moved from Strong Oversold to Oversold on October 1, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$1.16
• Last changeMoved from Strong Oversold to Oversold on October 1, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Inovio Pharmaceuticals, Inc. (INO) is a high-risk, clinical-stage biotech with valuation reflecting scant near-term commercial visibility. The company’s outlook depends heavily on discrete clinical readouts, potential partnerships and access to financing; absent positive catalysts the stock is likely to remain volatile and sensitive to broader risk-off flows. Financial health is constrained by ongoing cash burn and a history of capital raises, increasing dilution risk. Competitive and regulatory/payer pressures add downside for any future commercial assets. Near-term scenarios include a positive readout or partnership that materially uplifts value, or continued funding-driven dilution and muted trading if catalysts do not materialize.

Key factors

• Low current valuation and sub-$2 share price implies limited upside priced in; market has low expectations
• Clinical-stage pipeline: upside tied to binary clinical readouts or partnership/licensing deals that could re-rate the stock
• Weak financial position historically (cash burn and recurring need for financing) increases dilution risk absent near-term revenue or financing
• Small-cap biotech is sensitive to market-wide risk-off flows and healthcare IPO / funding windows that are currently cooling
• Potential positive catalysts include positive trial data, strategic partnership or non-dilutive financing and licensing opportunities
• Limited commercialization footprint; company would likely need partners to scale any approved product

Risks

• Clinical trial failures or safety setbacks that eliminate near-term value drivers
• Significant near-term dilution from equity raises to extend cash runway
• Regulatory setbacks or delays that push timelines and increase cash requirements
• Macro/sector risk-off environment reducing access to capital and depressing small-cap biotech multiples
• Policy/payer pressure (drug-price scrutiny, Medicare negotiation) that could compress future pricing power for specialty therapies
• Competition from better-funded peers or alternative therapeutic modalities that reduce addressable market and pricing

Latest MarketMoodz coverage

• Hantavirus outbreak sparks pharma rally; Moderna leads gains2026-05-11

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.